Innovation Pharmaceuticals Inc (IPIX)

[F1ash]

I realize the discussion is about trial size/duration not efficacy but, I believe that SGX942 is probably DOA. The lowest dose was the most effective dose. The higher doses performed worse than the lowest dose. An inverse response curve? Seems to me it would probably have a higher than average chance of failure even if the money to run the Phase 3 trial fell into their lap from heaven.

UP/UC is the brass ring imho. I will be satisfied if B-OM matches preclinical results at the interim review and verifies its anti-inflammatory properties on mucosa for use in UP/UC. That's where I believe the demand is greatest.